免疫治疗相关的疗效评价术语 - qitaijk.cn
持续临床获益（durable clinical benefit，DCB）：包括CR，PR和SD>6个月的患者. 无持续获益（non-durable clinical benefit，NDB)：包括SD⩽6个月和PD的患者. 【参考文献】 Molecular Determinants of Response to Anti–Programmed Cell Death (PD)-1 and Anti–Programmed Death-Ligand (PD-L)-Ligand 1 Blockade in Patients With Non–Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing.
Peripheral Artery Disease Intervention: Drug-Coated Balloon vs …
2022年8月27日 · Objectives: The aim of the study is to evaluate current trends and long-term durability of both drug-eluting stents (DES) and drug-coated balloons (DCB) in the treatment of peripheral artery disease (PAD). Background: PAD affects more than 200 million people worldwide. Endovascular treatment of critical PAD has advanced in recent years.
Outcomes of non-flow-limiting spiral dissection after drug-coated ...
Background: Whether drug-coated balloon (DCB) angioplasty would be effective in spiral dissection (SD) lesions with no flow impairment has been thoroughly investigated. Aims: The present study sought to assess the clinical outcomes of non-flow-limiting SD after DCB angioplasty for de novo femoropopliteal lesions in patients with symptomatic ...
Nationwide trends in drug-coated balloon and drug-eluting stent ...
Objective: Drug-coated balloons (DCB) and drug-eluting stents (DES) have significantly altered treatment paradigms for femoropopliteal lesions. We aimed to describe changes in practice patterns as a result of the infusion of these technologies into the treatment of …
6+思路带你了解基因突变标志物和免疫检查点抑制剂治疗效果的关 …
DCB定义为完全缓解 (CR)、部分缓解 (PR)或持续6个月以上的稳定疾病 (SD); 疾病进展 (PD)或稳定疾病 (SD)持续少于6个月视为无持久获益 (NDB)。 最终一共有来自五种癌症类型的386名接受ICIs治疗的患者被纳入该发现集。 同时作者从 cBioPortal 中检索并过滤了Samstein等收集的仅包含总生存数据和基因组数据的独立泛癌症数据集作为 验证集 (Validate cohort) 来验证EPHA7突变的预测功能。 其中在EPHA7编码区存在非同义体细胞突变的肿瘤定义为 EPHA7突变型 (EPHA7 …
OS、DFS、PFS、CR、PR、SD、PD，ORR，DCR都是啥？一文汇 …
疾病控制率指按照公认的缓解评价标准（如实体瘤 RECIST 1.1 版），肿瘤经治疗后获得缓解（PR+CR）和病变稳定（SD）并能维持最低时限要求的患者比例。 病变进展指肿瘤靶病灶最大径之和至少增加≥20%，或出现新病灶。 病变稳定指肿瘤靶病灶最大径之和缩小未达PR，或增大未 …
Safety and Efficacy of Drug-Coated Balloons Versus Drug-Eluting …
2022年1月10日 · Drug-coated balloons (DCBs) are an established treatment strategy for coronary artery disease. Randomized data on the application of DCBs in patients with an acute coronary syndrome (ACS) are limited.
Drug-Coated Balloon for De Novo Coronary Artery Disease:
Percutaneous coronary intervention with a drug-eluting stent is the most common mode of revascularization for coronary artery disease. However, restenosis rates remain high. Non-stent-based local drug delivery by a drug-coated balloon (DCB) has been investigated, as it …
Drug-Coated Balloon Angioplasty of the Side Branch
2025年1月14日 · DCB-BIF is the first powered, large, randomized controlled trial to compare the outcomes of a DCB vs NCB intervention for the SB in a large population with true coronary bifurcation lesions treated by a provisional stenting approach.
Drug-Coated Balloon Update: Are All DCBs the Same?
New paclitaxel DCB meta-analyses and trials show that there is no increased risk of all-cause mortality. The EffPac trial demonstrated that Luminor DCB is safe and effective with no increased risk of mortality.